5-methoxy-3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4(1H)-one | 1361967-03-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-methoxy-3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4(1H)-one
• 英文别名: 5-methoxy-3-methyl-2-[6-[4-(trifluoromethoxy)phenyl]-3-pyridyl]-1H-quinolin-4-one；5-methoxy-3-methyl-2-[6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl]-1H-quinolin-4-one
• CAS: 1361967-03-4
• 化学式: C₂₃H₁₇F₃N₂O₃
• 分子量: 426.395
• InChiKey: VWTKWUSONRRGMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-溴-5-醛基吡啶 在 四(三苯基膦)钯 、 三氟甲磺酸 、 potassium carbonate 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 正丁醇 为溶剂， 反应 27.0h， 生成 5-methoxy-3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4(1H)-one
  参考文献：
  名称：

  2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties

  摘要：

  描述了具有改善溶解性、改善代谢稳定性、减少非靶标毒性和12 nM Plasmodium falciparum 抗疟活性的2-吡啶基喹啉类化合物。

  DOI：

  10.1039/c5md00062a

文献信息

• Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor
  申请人：Liverpool School of Tropical Medicine

  公开号：US10799494B2

  公开（公告）日：2020-10-13

  The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.

  本发明涉及一种包含一种或多种呼吸电子传递链抑制剂和细胞色素bd抑制剂（如本文所定义）或其药学上可接受的盐的组合治疗产品。本发明还涉及包含该组合治疗产品的药物组合物，以及该组合治疗产品在治疗结核病等分枝杆菌感染中的用途。
• Identification, Design and Biological Evaluation of Heterocyclic Quinolones Targeting <i>Plasmodium falciparum</i> Type II NADH:Quinone Oxidoreductase (PfNDH2)
  作者：Suet C. Leung、Peter Gibbons、Richard Amewu、Gemma L. Nixon、Chandrakala Pidathala、W. David Hong、Bénédicte Pacorel、Neil G. Berry、Raman Sharma、Paul A. Stocks、Abhishek Srivastava、Alison E. Shone、Sitthivut Charoensutthivarakul、Lee Taylor、Olivier Berger、Alison Mbekeani、Alasdair Hill、Nicholas E. Fisher、Ashley J. Warman、Giancarlo A. Biagini、Stephen A. Ward、Paul M. O’Neill

  DOI：10.1021/jm201184h

  日期：2012.3.8

  Following a program undertaken to identify hit compounds against NADH:ubiquinone oxidoreductase (PfNDH2), a novel enzyme target within the malaria parasite Plasmodium falciparum, hit to lead optimization led to identification of CK-2-68, a molecule suitable for further development. In order to reduce ClogP and improve solubility of CK-2-68 incorporation of a variety of heterocycles, within the side chain of the quinolone core, was carried out, and this approach led to a lead compound SL-2-25 (8b). 8b has IC(50)s in the nanomolar range versus both the enzyme and whole cell P. falciparum (IC50 = 15 nM PfNDH2; IC50 = 54 nM (3D7 strain of P. falciparum) with notable oral activity of ED50/ED90 of 1.87/4.72 mg/kg versus Plasmodium berghei (NS Strain) in a murine model of malaria when formulated as a phosphate salt. Analogues in this series also demonstrate nanomolar activity against the bc(1) complex of P. falciparum providing the potential added benefit of a dual mechanism of action. The potent oral activity of 2-pyridyl quinolones underlines the potential of this template for further lead optimization studies.
• COMBINATION PRODUCT
  申请人：Liverpool School of Tropical Medicine

  公开号：US20190151305A1

  公开（公告）日：2019-05-23

  The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.
• 2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties
  作者：Sitthivut Charoensutthivarakul、W. David Hong、Suet C. Leung、Peter D. Gibbons、Paul T. P. Bedingfield、Gemma L. Nixon、Alexandre S. Lawrenson、Neil G. Berry、Stephen A. Ward、Giancarlo A. Biagini、Paul M. O'Neill

  DOI：10.1039/c5md00062a

  日期：——

  2-Pyridylquinolones with improved solubility, an improved metabolic stability profile, reduced off-target toxicity and 12 nM Plasmodium falciparum antimalarial activity are described.

  描述了具有改善溶解性、改善代谢稳定性、减少非靶标毒性和12 nM Plasmodium falciparum 抗疟活性的2-吡啶基喹啉类化合物。